Skip to main content

BeiGene

BeiGene Ltd is a global biotechnology company engaged in the discovery, clinical development, and commercialization of innovative oncology therapeutics. The company specializes in targeted small molecule therapies and immuno-oncology agents designed to treat hematologic malignancies and solid tumors. Its core product portfolio features the proprietary BTK inhibitor Brukinsa and the anti-PD-1 antibody Tevimbra, alongside licensed commercial oncology products. Primary revenues stem from worldwide commercial sales of its flagship cancer medicines, with major geographic end markets in the United States, China, and Europe. The enterprise occupies a prominent position in global oncology innovation due to its extensive clinical development infrastructure and commercial reach. BeiGene Ltd maintaining operational headquarters in Beijing, China, and trades publicly on the Nasdaq Global Select Market, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange.

33 of the funds FundTelligence covers report a position in BeiGene.

Legal name
BeiGene Ltd
Sector
Health Care
Country
China
Funds holding it
33

Funds holding BeiGene

Showing the 8 largest of 33 funds holding it.

Loading...